Otis Brawley leaves the American Cancer Society as it pursues “open-for-business” strategy amid sliding revenues

Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say

Anthony G. Letai, a physician-scientist at Harvard Medical School and Dana-Farber Cancer Institute whose research is focused on apoptosis and functional diagnostics, has been tapped by the Trump administration to become the 18th director of the National Cancer Institute.

September 25, 2025

By Claire Marie Porter and Paul Goldberg

Podcast

Congress seems to have NCI’s back—is cautious optimism warranted? Two former directors say yes.

With the fiscal year drawing to a close, grant funding from NCI is picking up speed, offering a glimmer of hope to cancer researchers who are beginning to feel cautiously optimistic about the road ahead.

September 24, 2025

NCI is “really, really sturdy” and won’t break, former directors Ned Sharpless and Kim Rathmell say at UNC Lineberger symposium

Grants are flowing out of NCI again to beat the fiscal-year end deadline and some cancer researchers are starting to feel cautiously optimistic about the future.

NCI releases names of members of ad hoc working group—filling the void left by BSA

NCI has released the names of the members of the newly formed ad hoc Working Group on Extramural Research Concepts and Programs. The group will perform the peer review functions of the now-defunct Board of Scientific Advisors.

September 19, 2025

Vol.51 No.34

By Sara Willa Ernst

AACR Cancer Progress Report makes the case for federal investment in cancer research

As NCI and NIH funding is being deliberated in Congress, this year’s 2025 AACR Cancer Progress Report had an unequivocal message: With 20 new anticancer therapeutics, new uses for eight previously approved anticancer therapeutics, two new early detection tools, and several AI-powered diagnostics approved over the span of just one year, cancer research funding yields a good return on investment.

Urgently needed: A funding mechanism to insulate cancer research from political whims

Jonathan Mahler’s article in the Sept. 14 issue of The New York Times Magazine provided an excellent overview of the Trump administration’s assault on cancer research.

September 19, 2025

Vol.51 No.34

By Paul W. Thurman

Otis Brawley leaves the American Cancer Society as it pursues “open-for-business” strategy amid sliding revenues

YOU MAY BE INTERESTED IN

Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say

Congress seems to have NCI’s back—is cautious optimism warranted? Two former directors say yes.

NCI is “really, really sturdy” and won’t break, former directors Ned Sharpless and Kim Rathmell say at UNC Lineberger symposium

NCI releases names of members of ad hoc working group—filling the void left by BSA

AACR Cancer Progress Report makes the case for federal investment in cancer research

Urgently needed: A funding mechanism to insulate cancer research from political whims

Renew today!

Subscriber content

Never miss an issue!

Login

Otis Brawley leaves the American Cancer Society as it pursues “open-for-business” strategy amid sliding revenues

YOU MAY BE INTERESTED IN

Anthony G. Letai to be named NCI directorThe Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say

Congress seems to have NCI’s back—is cautious optimism warranted? Two former directors say yes.

NCI is “really, really sturdy” and won’t break, former directors Ned Sharpless and Kim Rathmell say at UNC Lineberger symposium

NCI releases names of members of ad hoc working group—filling the void left by BSA

AACR Cancer Progress Report makes the case for federal investment in cancer research

Urgently needed: A funding mechanism to insulate cancer research from political whims

Never miss an issue!

Login

Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say